# Generare Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/generare-bioscience

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.generare.bio
- Total disclosed funding: $27M
- Latest round: Series A (Apr 2, 2026)
- Investors on record: 8

## About

Based in Paris, France and founded in 2022, Generare Bioscience is a biotechnology research company that provides a platform for identifying and expressing naturally occurring secondary metabolites for pharmaceutical development.In April 2026, Generare Bioscience raised EUR 20 million in series A funding.
Generare is a biotechnology company focused on discovering and producing natural chemicals made from microbial DNA. The company uses modern cloning techniques to accelerate the discovery of compounds that could be used to develop medications like antibiotics and cancer therapies. The firm is ffocused on the chemical variation found in microorganisms, the majority of which has yet to be discovered. Generare's mission is to fight antibiotic resistance while also benefiting society and the environment. The company will use the April 2026 funding to increase its drug discovery compound library, grow its team, and scale its discovery platform.

## Funding rounds

- Series A, Apr 2, 2026, $23M — Alven, Vives, Daphni, Galion.exe, Teampact Ventures, Better Angle
- Seed, Oct 7, 2024, $3.7M — Vives, Galion.exe, Saras Capital, SynBioVen, Teampact Ventures, Better Angle

## Investors

- Vives (https://capitalatlas.ai/funds/vives) — Seed, Series A
- Galion.exe (https://capitalatlas.ai/funds/galion-exe) — Seed, Series A
- Saras Capital (https://capitalatlas.ai/funds/saras-capital) — Seed
- SynBioVen (https://capitalatlas.ai/funds/synbioven) — Seed
- Teampact Ventures (https://capitalatlas.ai/funds/teampact-ventures) — Seed, Series A
- Better Angle (https://capitalatlas.ai/funds/better-angle) — Seed, Series A
- Alven (https://capitalatlas.ai/funds/alven) — Series A
- Daphni (https://capitalatlas.ai/funds/daphni) — Series A